HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.03530509v1 4/11/1858    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Rovin, B. H. Articles by Zhang, X. PubMed PubMed Citation Articles by Rovin, B. H. Articles by Zhang, X.

Biomarkers for Lupus Nephritis: The Quest Continues

Division of Nephrology, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio

Correspondence: Dr. Brad H. Rovin,Division of Nephrology, Ohio State University College of Medicine, 395 W. 12th Avenue, Ground Floor, Columbus, OH 43210. Phone: 614-293-4997; Fax: 614-293-3073; E-mail: Rovin.1{at}osu.edu

Current treatment of severe lupus nephritis is unsatisfactory in terms of both outcome and toxicity. To improve the efficacy and decrease the adverse effects of immunosuppression, it would be ideal to be able to predict the course and pathology of lupus nephritis and adjust therapy appropriately. This will require biomarkers that reflect disease activity. Recently, significant effort has been put into identifying biomarkers that can anticipate impending lupus renal flare, forecast development of chronic kidney disease, or reflect kidney histology at the time of flare. Although these biomarkers are potentially useful, to date none has been clinically validated in a large, prospective cohort of patients with SLE. This article reviews the current status of lupus nephritis biomarker investigation and articulates a perspective of how future efforts should be focused.